StemMedical A/S, Gyngemose Parkvej 50, 2860, Copenhagen, Denmark.
Department of Plastic Surgery, Aleris Hospitals, Gyngemose Parkvej 66, 2860, Copenhagen, Denmark.
Aesthetic Plast Surg. 2024 Jan;48(2):98-115. doi: 10.1007/s00266-023-03711-6. Epub 2023 Dec 4.
BACKGROUND: Fat grafting is commonly utilized in breast surgery, and since it was first described, clinicians and researchers have stridden towards improvement of graft retention. Current advancements include adding adipose-derived mesenchymal stem/stromal cells (MSC(AT)s), which have demonstrated promise for improved graft retention. OBJECTIVES: This study reports outcomes for the first twenty-two patients undergoing breast augmentation (Stemform BA) or artificial implant replacement (Stemform AIR) with MSC(AT)-enriched fat in a real-world setting. METHODS: Autologous MSC(AT)s were isolated and expanded ex vivo, then mixed with lipoaspirate and injected as enriched fat for Stemform BA and AIR. The breast volume was measured preoperatively and at 3 and 12 months postoperative using a 3D Infinity Dual-Lens Camera and LifeVizApp software. Additionally, independent plastic surgeons evaluated clinical images, and patient satisfaction was obtained at equal time points. RESULTS: Twenty-two patients were included. All completed 3 and 12 months clinical follow-up and 3 months volume measurements. Nineteen patients completed 12 months volume measurements. The median fat graft retention at 12 months was 95.7% (IQR = 82.44-103.12%) for Stemform BA patients and 113.0% (IQR = 94.8-131.2%) for Stemform AIR patients. The Stemform BA patients had a median breast enlargement of 172.0% (IQR = 156.7-241.0%). The implant replacement volume of Stemform AIR patients was 102% (IQR = 85.1-130.3%). The patient reported 92.8% and 100% would elect to repeat treatment if they had the opportunity for Stemform BA and Stemform AIR, respectively. CONCLUSION: Breast augmentation and breast implant replacement patients receiving ex vivo-expanded MSC(AT)-enriched fat grafts had high graft retention and patient satisfaction scores. The paper confirms the clinical efficacy of using ex vivo-expanded MSC(AT)s. Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
背景:脂肪移植在乳房手术中被广泛应用,自首次描述以来,临床医生和研究人员一直在努力提高移植物的保留率。目前的进展包括添加脂肪来源的间充质干细胞/基质细胞(MSC(AT)s),这已被证明有助于提高移植物的保留率。
目的:本研究报告了 22 例在真实环境中接受富含 MSC(AT)脂肪的乳房隆乳术(Stemform BA)或人工植入物置换术(Stemform AIR)患者的治疗结果。
方法:自体 MSC(AT)s 经体外分离和扩增,然后与脂肪抽吸物混合并注射为富含脂肪的 Stemform BA 和 AIR。术前和术后 3 个月和 12 个月使用 3D Infinity 双镜头相机和 LifeVizApp 软件测量乳房体积。此外,独立的整形外科医生评估了临床图像,并在相同时间点获得了患者满意度。
结果:共纳入 22 例患者。所有患者均完成了 3 个月和 12 个月的临床随访和 3 个月的体积测量。19 例患者完成了 12 个月的体积测量。Stemform BA 患者的中位脂肪移植物保留率为 12 个月时为 95.7%(IQR=82.44-103.12%),Stemform AIR 患者为 113.0%(IQR=94.8-131.2%)。Stemform BA 患者的乳房增大中位数为 172.0%(IQR=156.7-241.0%)。Stemform AIR 患者的植入物置换体积为 102%(IQR=85.1-130.3%)。如果有机会进行 Stemform BA 和 Stemform AIR,患者分别报告 92.8%和 100%愿意再次接受治疗。
结论:接受体外扩增 MSC(AT)脂肪移植物的乳房隆乳术和乳房植入物置换术患者的移植物保留率和患者满意度评分较高。本文证实了使用体外扩增 MSC(AT)s 的临床疗效。证据水平 V 本刊要求作者为每篇文章分配一个证据级别。有关这些循证医学评级的完整描述,请参考目录或在线作者指南 www.springer.com/00266 。
Aesthetic Plast Surg. 2022-8
Aesthetic Plast Surg. 2018-12
Aesthetic Plast Surg. 2023-10
Expert Rev Clin Immunol. 2022-1
Aesthet Surg J. 2021-5-18
Plast Reconstr Surg Glob Open. 2017-10-20
Clin Plast Surg. 2015-7
Plast Reconstr Surg. 2014-3
J Plast Surg Hand Surg. 2012-4